A Multi-centre, Multinational, Prospective Observational Registry to Collect Safety and Outcome Data in Patients Diagnosed With Severe Hepatic VOD Following Hematopoietic Stem Cell Transplantation (HSCT) and Treated With Defitelio® or Supportive Care (Control Group)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 31 Jul 2018
At a glance
- Drugs Defibrotide (Primary)
- Indications Veno-occlusive disorders
- Focus Adverse reactions
- 23 Jul 2018 Planned End Date changed from 1 Dec 2018 to 17 Jul 2019.
- 23 Jul 2018 Planned primary completion date changed from 1 Jun 2018 to 17 Jul 2019.
- 23 Jul 2018 Status changed from recruiting to active, no longer recruiting.